Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 10, 2016 - Issue 1
Submit an article Journal homepage
645
Views
17
CrossRef citations to date
0
Altmetric
Drug Profiles

Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction

John J. BrewingtonDivision of Pulmonary Medicine, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, USA
,
Gary L. McPhailDivision of Pulmonary Medicine, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, USA
&
John P. ClancyDivision of Pulmonary Medicine, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, USACorrespondence[email protected]
Pages 5-17 | Published online: 09 Dec 2015

References

  • Papers of special note have been highlighted as:
  • • of interest
  • •• of considerable interest
  • Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992–2001.
  • Pilewski JM, Frizzell RA. Role of CFTR in airway disease. Physiol Rev. 1999 Jan;79(1 Suppl):S215–S255.
  • Foundation NACF. 2013 North American CFF annual data report to center directors [Internet]. 2013. [cited 2015 Oct 15]. Available from: https://www.cff.org/2013_CFF_Annual_Data_Report_to_the_Center_Directors.pdf
  • CFF JHM. CFTR2 database [Internet]. 2015. [cited 2015 Jul 28]. Available from: www.cftr2.org
  • Anderson MP, Gregory RJ, Thompson S, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science. 1991 Jul 12;253(5016):202–205.
  • Schweibert EM, Benos DJ, Egan ME, et al. CFTR Is a conductance regulator as well as a chloride channel. Physiol Rev Am Physiol Soc. 1999; 79(1 Suppl);S145–S166.
  • Hudson VM. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic Biol Med. 2001;30(12):1440–1461.
  • Moskwa P, Lorentzen D, Excoffon KJ, et al. A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med. 2007 Jan 15;175(2):174–183.
  • Park M, Ko SB, Choi JY, et al. The cystic fibrosis transmembrane conductance regulator interacts with and regulates the activity of the HCO3- salvage transporter human Na+-HCO3- cotransport isoform 3. J Biol Chem. 2002 Dec 27;277(52):50503–50509.
  • Engelhardt JF, Yankaskas JR, Ernst SA, et al. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet. 1992;2(3):240–248.
  • Engelhardt JF, Zepeda M, Cohn JA, et al. Expression of the cystic fibrosis gene in adult human lung. J Clin Invest. 1994;93(2):737–749.
  • Meyerholz DK, Stoltz DA, Namati E, et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. Am J Respir Crit Care Med. 2010 Nov 15;182(10):1251–1261.
  • Cohn JA, Strong TV, Picciotto MR, et al. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology. 1993;105(6):1857–1864.
  • Grubb BR, Gabriel SE. Intestinal physiology and pathology in gene-targeted mouse models of cystic fibrosis. Am J Physiol. 1997 Aug;273(2 Pt 1):G258–G266.
  • Marino CR, Matovcik LM, Gorelick FS, et al. Localization of the cystic fibrosis transmembrane conductance regulator in pancreas. J Clin Invest. 1991 Aug;88(2):712–716.
  • Patrizio P, Asch RH, Handelin B, et al. Aetiology of congenital absence of vas deferens: genetic study of three generations. Hum Reprod. 1993 Feb;8(2):215–220.
  • Reddy MM, Bell CL, Quinton PM. Cystic fibrosis affects specific cell type in sweat gland secretory coil. Am J Physiol. 1997 Aug;273(2 Pt 1):C426–33.
  • Stoltz DA, Rokhlina T, Ernst SE, et al. Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs. J Clin Invest. 2013;123(6):2685–2693.
  • Joo NS, Irokawa T, Wu JV, et al. Absent secretion to vasoactive intestinal peptide in cystic fibrosis airway glands. J Biol Chem. 2002 Dec 27;277(52):50710–50715.
  • Wu JV, Krouse ME, Wine JJ. Acinar origin of CFTR-dependent airway submucosal gland fluid secretion. Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L304–11.
  • Joo NS, Irokawa T, Robbins RC, et al. Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands. J Biol Chem. 2006;281(11):7392–7398.
  • Joo NS, Lee DJ, Winges KM, et al. Regulation of antiprotease and antimicrobial protein secretion by airway submucosal gland serous cells. J Biol Chem. 2004 Sep 10;279(37):38854–38860.
  • Choi JY, Joo NS, Krouse ME, et al. Synergistic airway gland mucus secretion in response to vasoactive intestinal peptide and carbachol is lost in cystic fibrosis. J Clin Invest. 2007;117(10):3118–3127.
  • Wine JJ, Joo NS. Submucosal glands and airway defense. Proc Am Thorac Soc. 2004;1(1):47–53.
  • Chen JH, Stoltz DA, Karp PH, et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell. 2010 Dec 10;143(6):911–923.
  • Hoegger MJ, Fischer AJ, McMenimen JD, et al. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science (New York, NY). 2014 Aug 15;345(6198):818–822.
  • Quinton PM. Role of epithelial HCO3- transport in mucin secretion: lessons from cystic fibrosis. Am J Physiol Cell Physiol. 2010;299(6):C1222–C1233.
  • Quinton PM. The neglected ion: HCO3. Nat Med. 2001 Mar;7(3):292–293.
  • Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet. 2008;372(9636):415–417.
  • Ehre C, Ridley C, Thornton DJ. Cystic fibrosis: an inherited disease affecting mucin-producing organs. Int J Biochem Cell Biol. 2014 Jul;52:136–145.
  • Yang N, Garcia MA, Quinton PM. Normal mucus formation requires cAMP-dependent HCO3- secretion and Ca2+-mediated mucin exocytosis. J Physiol. 2013;591(Pt 18):4581–4593.
  • Gray T, Coakley R, Hirsh A, et al. Regulation of MUC5AC mucin secretion and airway surface liquid metabolism by IL-1beta in human bronchial epithelia. Am J Physiol Lung Cell Mol Physiol. 2004;286(2):L320–L330.
  • Kesimer M, Ehre C, Burns KA, et al. Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways. Mucosal Immunol. 2013;6(2):379–392.
  • Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med. 2007 Jan;261(1):5–16.
  • Matsui H, Randell SH, Peretti SW, et al. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Investig. 1998;102(6):1125–1131.
  • Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med. 2007;58:157–170.
  • Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006 Jan 19;354(3):241–250.
  • Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol. 1997;24(2):137–142; discussion 59–61.
  • Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med. 2007 Jun;28(2):331–346.
  • Cohen-Cymberknoh M, Kerem E, Ferkol T, et al. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013 Dec;68(12):1157–1162.
  • Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol Med. 2012 Feb;18(2):81–91.
  • Wang B, Heath-Engel H, Zhang D, et al. BAP31 interacts with Sec61 translocons and promotes retrotranslocation of CFTRDeltaF508 via the derlin-1 complex. Cell. 2008 Jun 13;133(6):1080–1092.
  • Carvalho-Oliveira I, Efthymiadou A, Malho R, et al. CFTR localization in native airway cells and cell lines expressing wild-type or F508del-CFTR by a panel of different antibodies. J Histochem Cytochem. 2004;52(2):193–203.
  • Denning GM, Ostedgaard LS, Welsh MJ. Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia. J Cell Biol. 1992 Aug;118(3):551–559.
  • Jurkuvenaite A, Chen L, Bartoszewski R, et al. Functional stability of rescued delta F508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells. Am J Respir Cell Mol Biol. 2010;42(3):363–372.
  • Linsdell P, Tabcharani JA, Hanrahan JW. Multi-Ion mechanism for ion permeation and block in the cystic fibrosis transmembrane conductance regulator chloride channel. J Gen Physiol. 1997 Oct;110(4):365–377.
  • Boinot C, Jollivet Souchet M, Ferru-Clement R, et al. Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing. J Pharmacol Exp Ther. 2014 Sep;350(3):624–634.
  • Nieddu E. Cystic fibrosis: CFTR modulators and their mechanism of action. Curr Pharm Des. 2013;19(19):3474–3475.
  • Clancy JP, Konstan MW, Rowe SM, et al. A phase II study of PTC124 in CF patients harboring premature stop mutations. Pediatr Pulmonol Suppl. 2006;41(S29):Abstract 269.
  • Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011 Nov 3;365(18):1663–1672.

• Phase 3 study of ivacaftor in CF patients with the G551D gating mutation.

  • Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991–2003.

• First report of ivacaftor treatment in CF patients.

  • Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013 Jun 1;187(11):1219–1225.

•• Phase 3 study of ivacaftor in pediatric CF patients with the G551D mutation.

  • Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843–18848.

•• In vitro characterization of lumacaftor (VX-809) in human lower airway epithelial cells.

  • Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012 Jan;67(1):12–18.

•• First report of lumacaftor treatment in CF patients homozygous for the F508del mutation.

  • Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527–538.

•• First demonstration of clinical efficacy of lumacaftor/ivacaftor combination therapy in CF patients homozygous for the F508del mutation.

  • Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220–231.

•• Landmark Phase 3 trials of lumacaftor/ivacaftor combination therapy in CF patients homozygous for the F508del mutation.

  • Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012;142(3):718–724.

• Phase 2 study of ivacaftor monotherapy in CF patients homozygous for the F508del mutation.

  • Eng PA, Morton J, Douglass JA, et al. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol. 1996;21(2):77–83.
  • Hubbard RC, McElvaney NG, Birrer P, et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med. 1992 Mar 19;326(12):812–815.
  • Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis. 1993;148(1):145–151.
  • Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 1997;52(10):900–903.
  • Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. Jama. 2003 Oct 1;290(13):1749–1756.
  • Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet. 2001 Oct 20;358(9290):1316–1321.
  • Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57(3):212–216.
  • Treatment with VX-661 and ivacaftor in a phase 2 study resulted in statistically significant improvements in lung function in people with cystic fibrosis who have two copies of the F508del mutation [Internet]. Vertex Pharmaceuticals, Inc; 2013 [cited 2015 Jul 28]. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=757597
  • Vertex announces recent Progress and Upcoming Milestones in Research and Development Programs for Cystic Fibrosis [Internet]. Vertex Pharmaceuticals, Inc; 2013 [cited 2015 Jul 28]. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=798106
  • Addition of VX-661 to KALYDECO® (ivacaftor) improves lung function in people with CF who are heterozygous for the F508del and G551D mutations in 28-day phase 2 proof-of-concept study [Internet] Vertex Pharmaceuticals, Inc; 2014 [cited 2015 Jul 28]. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=844677
  • Orkambi package insert [Internet]. Vertex Pharmaceuticals, Inc; 2015 [cited 2015 Aug 3]. Available from: http://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf
  • Balfour-Lynn IM. Personalised medicine in cystic fibrosis is unaffordable. Paediatr Respir Rev. 2014 Jun;15(Suppl 1):2–5.
  • Cohen D, Raftery J. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding. BMJ (Clinical Research Ed). 2014;348:g1445.
  • Whiting P, Al M, Burgers L, et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014;18(18):1–106.
  • Cholon DM, Quinney NL, Fulcher ML, et al. Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR in cystic fibrosis. Sci Transl Med. 2014 Jul 23;6(246):246ra96.
  • Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Sci Transl Med. 2014 Jul 23;6(246):246ra97.
  • Clancy JP. CFTR potentiators: not an open and shut case. Sci Transl Med. 2014;6(246):246fs27.
  • Alton EW, Stern M, Farley R, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 1999 Mar 20;353(9157):947–954.
  • Dekkers JF, Wiegerinck CL, De Jonge HR, et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med. 2013;19(7):939–945.
  • Subbarao P, Stanojevic S, Brown M, et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. Am J Respir Crit Care Med. 2013 Aug 15;188(4):456–460.
  • Phuan PW, Veit G, Tan J, et al. Potentiators of defective deltaF508-CFTR channel gating that do not interfere with corrector action. Mol Pharmacol. 2015;88(4):791–799.
  • Rowe SM, Clancy JP. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. BioDrugs. 2009;23(3):165–174.
  • Kerem E, Konstan MW, De Boeck K, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014;2(7):539–547.
  • Herzog RW, Cao O, Srivastava A. Two decades of clinical gene therapy–success is finally mounting. Discov Med. 2010 Feb;9(45):105–111.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.